On June 24th, Gelunhui announced that as of the fiscal year ending March 31, 2024, the company's revenue was about 190 million Hong Kong dollars, a year-on-year decrease of about 10.7%. The Group recorded a loss of about 75.8 million Hong Kong dollars for the fiscal year ending March 31, 2024, compared to a loss of 3.2 million Hong Kong dollars for the fiscal year ending March 31, 2023. Shareholders' loss per share is 14.4 Hong Kong cents.

The company generates revenue by providing private ophthalmic services in Hong Kong (including refractive treatment, treatment of other eye problems, diagnostic and examination services, as well as sales of prescription drugs and vision products). In the face of increasingly severe business pressures, the company has implemented strategic measures to address these challenges and promote growth. One notable initiative is the establishment of a new medical center in Tsim Sha Tsui in July 2023, which is dedicated to the prevention and control of myopia in children. This investment is in line with the company's commitment to providing quality medical services in this specific field and providing specialized care.

The company remains committed to providing excellent ophthalmic services and navigating through uncertainty while driving growth. The company is focused on professional knowledge, advanced technology and personalized patient care. The company will explore innovative strategies to enhance its value proposition, diversify its sources of revenue, and seize new growth opportunities while ensuring cost efficiency. With the company's adaptability and advantages, the company is confident that it can overcome challenges and achieve long-term growth.